[if gte mso 9] > < xml >
between 30% and 40% of the people of Madrid suffers from hypertensionblood
the Madrid Association of hypertension (SOMHA) andBoehringer Ingelheim convened the 13th edition of cases clinical envelopehigh blood pressure and cardiovascular risk
-these regional Awards winner opts for the awardNational delivered at the national meeting of the Spanish society ofSpanish hipertensión-Liga to combat Arterial hypertension(SEH-LELHA)
Рen mayores de 65 a̱os, prevalence rises up60%
– only one of every two or three hypertensive is controlled
– la Comunidad de Madrid benefits from the high level of theclinical doctors work in primary care and hospitals
Madrid, June of 2012- the prevalence of hypertensionblood (ETS) in the community of Madrid in middle ages ranges between 30% -40%. This figure is very similar to that of the rest of the country and the larger population65 increases up to 60%. The increase of obesity in the populationMadrid is causing an increase in this trend 1.
of the relationship between hypertension and cardiovascular riskborn the common interest of the Sociedad Española de Hipertensión-Liga Españolafor the fight against Arterial hypertension (SEH-LELHA), the AssociationArterial hypertension (SOMHA) and Boehringer Ingelheim to boost Madridthe research and scientific development in this field.
as result of this common interest, the SOMHA convenes 182012 October the 13th edition of clinical cases on hypertensionBlood and Cardiovascular risk with thegoal of highlighting excellence in the detection, evaluation and control of thehypertensive patient made at the Spanish health system, both inPHC in hospital units of high blood pressure andcardiovascular risk.
a few prestigious national awards
the contest consists of two phases: the first presentsclinical cases to each regional society, from where they are valued and areprovides a selection of projects by virtue of which will select thecase representing each. In the second, at the national level, they will competeall previously selected cases and shall be elected the winner by criteriaobjectives through vote, according to the originality of the case, its presentation orthe excellence of the diagnostic procedures used.
these awards have become a national point of reference andthey have one ever-increasing tracking, having been presented at the lastEdition 150 projects. According to Dr. José Abellán, national coordinator of thePrize, after twelve editions these prizes are great excitement andfollow-up, are fully consolidated and followed throughout the territoryNational. The presentation of clinical cases of hypertensive patients or withcardiovascular risk enables professionals to exchange experiences andlearn from monitoring applied in each case ”. In Madrid, Dr. AlbertoGreyhound Nafria, President of the SOMHA stresses that, this year has reached themaximum participation by sending 32 clinical cases of high-level ”.
the SOMHA President satisfied with theattention given to the patient in the community of Madrid but ensuresthat there are problems of early detection of the HTA as well as the promotionhealthy habits from an early age. Moreover, is long journey incontrol and diagnosis of this pathology, only one of every two or threehypertensive, is controlled ”.
el Dr. Abellán stresses also that the educational level ofspecialized in HTA and RWT health is very high and they are verysensitized with the theme ” and explains that in the projects are increasinglymore taking into consideration how can contribute changes in styleslife to control the RWT ”. Meanwhile Dr. Greyhound Nafria clarifies that, theMadrid community benefited from the significant level of cliniciansworking in Madrid in primary care and in various hospitals ofnational level together much of the best specialists ofSpain ”.
Boehringer Ingelheim provide value through theinnovation ”
the Boehringer Ingelheim group is one of the 20 companiesof the world’s largest drug companies. Headquartered in Ingelheim, Germany, it worksglobally with 145 affiliated account with more than 44,000 partners/ACE.Since its foundation in 1885, the company’sfamily property is committed to the research, the development, theproduction and marketing of new products of high therapeutic valuefor animal and human medicine.
a central element of corporate culture of BoehringerIngelheim is committed to socially responsible actions. For this reason, thecompany is involved in social projects and take care of their collaborators as andfamilies, offering everyone equal opportunities. Respect, equality ofopportunities and reconciling working life and family arethe basis of mutual cooperation. As well as the protection of the environment andsustainability that are always present in any activity ofBoehringer Ingelheim.
Boehringer Ingelheim settled in Spain in 1952, and thethroughout these 60 years has evolved to the No. 10 position of thepharmaceutical sector in our country. The company is headquartered in Spain inSant Cugat del Vallès (Barcelona), and currently has about 1,700 employeesand two international production centres in Sant Cugat del Vallès and MalgratMar.
